Skip to main content

Day: June 20, 2025

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes. In connection with the offering, the Company will issue 1,180,877 shares of common stock (or pre-funded warrants to purchase shares of common stock) at a purchase...

Continue reading

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) — Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company’s common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq’s determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Specifically, Nasdaq cited the issuance of Series C voting convertible preferred stock and warrants to the Company’s placement agent and advisor to...

Continue reading

Sagteс Finalizes Strategic AI Acquisition to Accelerate SaaS Revenue and Multi-Sector AI Deployment

Definitive Agreement Signed to Acquire 80% of Smart Bridge Technology, a Profitable Agentic AI Platform KUALA LUMPUR, Malaysia, June 20, 2025 (GLOBE NEWSWIRE) — Sagtec Global Limited (NASDAQ: SAGT) (“Sagtec” or the “Company”), a next-generation provider of customizable AI and automation platforms, today announced the signing of a definitive Share Sale Agreement (SSA) to acquire an 80% equity stake in Smart Bridge Technology Limited (“Smart Bridge”), a rapidly scaling agentic AI software company with proven profitability.  The acquisition reinforces Sagtec’s strategic shift into an AI-first, SaaS-driven growth model. Closing remains subject to customary regulatory approvals and conditions. Profitable AI Acquisition to Fuel SaaS Margin Expansion Smart Bridge brings a profitable, enterprise-ready AI platform, having reported a net...

Continue reading

The European Space Agency and Dassault Aviation paving the way for potential collaborations

PRESS RELEASE June 20, 2025 The European Space Agency and Dassault Aviation paving the way for potential collaborations ESA and Dassault Aviation have identified a mutual interest in developing a closer relationship to commonly foster technology development in areas such as LEO destinations and particularly around orbital vehicules. The European Space Agency (ESA) has signed a Letter of Intent (LoI) with Dassault Aviation, a French civilian and military aircraft manufacturer recognized worldwide for its excellence, underlying their common interest to develop a closer relationship. ESA, with its ambitious strategy for space exploration, Explore2040, is seeking innovative solutions for capabilities development to reach and return from Low Earth Orbit (LEO), Moon and Mars, and supports the advancement of selected critical enabling technologies...

Continue reading

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application (IND) for GH001 to the U.S. Food and Drug Administration (FDA). “We are thrilled to have submitted our response to the FDA ahead of schedule, addressing their clear requests with comprehensive data and completed toxicology studies. We remain fully committed to working closely with the agency to bring GH001 to patients,” said Dr. Velichka Valcheva, Chief Executive Officer. About GH001 Our lead product candidate, GH001, is formulated for mebufotenin administration...

Continue reading

Nathan Bekke Named Chief Operating Officer

DAVENPORT, Iowa, June 20, 2025 (GLOBE NEWSWIRE) — Nathan Bekke, Operating Vice President and Vice President of Audience Strategy, has been named Chief Operating Officer of Lee Enterprises, Incorporated (NASDAQ:LEE). Kevin Mowbray, Lee’s President and Chief Executive Officer, said “Nathan has played an integral role in Lee’s transformation and has been a key leader in driving revenue and greatly increasing our digital audience that’s led to industry leading digital-only audience growth. He has also been a significant contributor to Lee with strong operational knowledge driving excellent results across the company. Among his many talents, Nathan has also demonstrated tremendous success consolidating legacy print costs that drive necessary efficiencies that allow the company to reinvest in our digital future. I join Lee’s Board of...

Continue reading

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First novel mechanism of action for CIDP treatment in more than 30 yearsJune 20, 2025, 7:00 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the European Commission (EC) approved VYVGART® (efgartigimod alfa) 1000mg for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins....

Continue reading

Support from the Ministry of the French Armed Forces for the development of Dassault Aviation’s VORTEX spaceplane demonstrator

Support from the Ministry of the French Armed Forces for the development of Dassault Aviation’s VORTEX spaceplane demonstrator (Saint-Cloud, June 20, 2025) – At the Paris Air Show today, Sébastien Lecornu, Minister of the French Armed Forces, and Eric Trappier, Chairman and CEO of Dassault Aviation, announced the signing of an agreement to support the development of a spaceplane demonstrator. This demonstrator represents the first step in an incremental and intrinsically dual roadmap for the development of a family of spaceplanes called VORTEX (Véhicule Orbital Réutilisable de Transport et d’Exploration). In line with its key role in national aeronautical sovereignty, Dassault Aviation is building this roadmap to contribute to the development of key strategic capabilities and meet the new challenges of the space economy....

Continue reading

Mike Lindell Media Corp. OTC: (MLMC) Features LindellTV Reporters on Capitol Hill and at the White House Reporting on the Agenda of President Trump and with Breaking Coverage on the Election Front With Mike Lindell.

LindellTV Covering News, Politics, and U.S. and World Events Like No Other Network Will Also Feature Colonel Conrad Reynolds with Mike Lindell. They Will Be Live today on LindellTV at 4:00 PM EDT Discussing Paper Ballots. Washington, D.C., June 20, 2025 (GLOBE NEWSWIRE) — Mike Lindell Media Corp. (OTC: MLMC) announced LindellTV will cover events on Capitol Hill with our D.C. reporter, Alison Steinberg who will provide daily coverage from the Hill with news and interviews of lawmakers and others on what matters most to those hungry for in-depth coverage.  Cara Castronuova, our Chief White House Correspondent will continue providing inside and outside coverage for LindellTV and Mike Lindell Media Corp. from the White House as President Trump moves his agenda forward. Mike Lindell, Chairman and Chief Executive Officer said, “LindellTV...

Continue reading

Amendment – this form replaces the form titled “Form 8.3 – dotDigital Group plc – Octopus Investments” published at 13.54 on 19/06/2025. Changes have been made to Section 1/Title

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Marlowe plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position held/dealing undertaken:...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.